— Titan Pharmaceuticals (NASDAQ: TTNP) reported Q3 2019 loss of $0.18 per share, vs. $0.21 expected. — Revenues fell 47% to approx. $0.9 million, vs. $0.7 million expected. — Product revenues totaled approx. $0.2 million. — Grant revenues totaled approx. $0.8 million. — R&D expenses amounted to approx. $1.6 million. — TTNP shares gained 1% […]
“— Titan Pharmaceuticals (NASDAQ: TTNP) reported Q3 2019 loss of $0.18 per share, vs. $0.21 expected. — Revenues fell 47% to approx. $0.9 million, vs. $0.7 million expected. — Product revenues totaled approx. $0.2 million. — Grant revenues totaled approx. $0.8 million. — R&D expenses amounted to approx. $1.6 million. — TTNP shares gained 1% […]
· November 14, 2019
— Titan Pharmaceuticals (NASDAQ: TTNP) reported Q3 2019 loss of $0.18 per share, vs. $0.21 expected.
— Revenues fell 47% to approx. $0.9 million, vs. $0.7 million expected.
— Product revenues totaled approx. $0.2 million.
— Grant revenues totaled approx. $0.8 million.
— R&D expenses amounted to approx. $1.6 million.
— TTNP shares gained 1% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
